Ad
ASMB Quote Trading Chart Assembly Biosciences Inc.
home / stock / asmb / asmb quote
$1.66 Last:
-0.88% Change Percent:
$1.725 Open:
$1.66 Previous Close:
$1.725 High:
$1.64 Low:
99,667 Volume:
12/31/1969 07:00:00 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
ASMB Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2022-09-29 | 1.725 | 1.66 | 1.725 | 1.64 | 99,667 |
| 2022-09-28 | 1.67 | 1.71 | 1.76 | 1.64 | 269,043 |
| 2022-09-27 | 1.66 | 1.66 | 1.685 | 1.63 | 155,048 |
| 2022-09-26 | 1.7 | 1.66 | 1.74 | 1.65 | 133,987 |
| 2022-09-23 | 1.77 | 1.7 | 1.79 | 1.67 | 270,322 |
| 2022-09-22 | 1.78 | 1.79 | 1.86 | 1.75 | 527,040 |
| 2022-09-21 | 1.84 | 1.8 | 1.85 | 1.78 | 228,966 |
| 2022-09-20 | 1.82 | 1.84 | 1.91 | 1.81 | 225,705 |
| 2022-09-19 | 1.9 | 1.82 | 1.9 | 1.81 | 194,490 |
| 2022-09-16 | 2.06 | 1.91 | 2.08 | 1.88 | 370,700 |
| 2022-09-15 | 2.09 | 2.09 | 2.16 | 2.0796 | 156,701 |
| 2022-09-14 | 2.13 | 2.07 | 2.17 | 2.04 | 380,182 |
| 2022-09-13 | 2.1 | 2.15 | 2.2 | 2.03 | 224,916 |
| 2022-09-12 | 2.09 | 2.14 | 2.16 | 2 | 360,343 |
| 2022-09-09 | 1.91 | 2.02 | 2.07 | 1.9 | 352,317 |
| 2022-09-08 | 1.91 | 1.9 | 1.96 | 1.875 | 177,386 |
| 2022-09-07 | 1.85 | 1.94 | 1.97 | 1.76 | 262,131 |
| 2022-09-06 | 1.93 | 1.85 | 1.95 | 1.81 | 394,725 |
| 2022-09-02 | 1.96 | 1.98 | 2.05 | 1.945 | 409,828 |
| 2022-09-01 | 1.89 | 1.93 | 1.94 | 1.83 | 193,472 |
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
Ad
-
- Renowned virologist, Nobel laureate and Assembly Bio board member, Sir Michael Houghton, PhD, will join company leadership for the discussion - SOUTH SAN FRANCISCO, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnolog...
-
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced financial results ...
-
- Discontinues clinical development of vebicorvir, Assembly Bio’s first-generation core inhibitor, based on interim efficacy data from ongoing combination clinical studies - Advancing next-generation, significantly more potent core inhibitors, ABI-H3733 and ABI-4334, in cli...